Changes to 2024 Quality Measures

Global Changes:

- **A laboratory claim exclusion has been added** to measures relying on diagnosis codes for patient inclusion in, or exclusion from, the measure. Diagnosis codes reported on laboratory claims are <u>NOT</u> considered.
- The method for identifying a patient with Diabetes has been modified: Patients dispensed a Diabetes medication (insulin or hypoglycemics/antihyperglycemics) must now also have at least one diagnosis of Diabetes during the measurement year (i.e., 2024) or the year prior (i.e., 2023).
- The list of Diabetes medications (insulin or hypoglycemics/antihyperglycemics) has been updated to include Metformin as a solo agent.
- The method for identifying a patient with Advanced Illness has been modified: Patients with Advanced Illness are now identified by <u>ANY TWO</u> encounters with an Advanced Illness code, or a dispensed Dementia medication, in the measurement year (i.e., 2024) or the year prior (i.e., 2023).
- A clarification has been added to result-dependent measures (e.g., Cervical Cancer Screening, DM HbA1c Control, etc.): "Unknown" is NOT a valid result.

Measure-Specific Changes

- Annual (Medicare) Wellness Visits: BCBSM/BCN (and PH) now allow subsequent AWVs to occur any time during a calendar year.
- Breast Cancer Screening: The eligible population for this measure has been modified from "female patients" to "any patient recommended for routine breast cancer screening". Please see NPO's "2024 Quality Measures Guide" for more details.
- Care Management: The following changes pertain to the Priority Health (PH) Care Management incentive program:
 - > The following care management codes are now recognized for touchpoint credit:
 - 98961 (Group Education: 2-4 patients)
 - 98962 (Group Education: 5-8 patients)
 - S0257 (End of Life Counseling)
 - 99497 (Advanced Care Planning)
 - 99498 (Advanced Care Planning)
 - > PH no longer dictates which quality measures must be met for the quality component of this incentive measure. NPO may select any three preventive health or chronic disease quality measures applicable to each product line.
- **Cervical Cancer Screening**: The eligible population for this measure has been modified from "female patients" to "those recommended for routine cervical cancer screening". Please see NPO's "2024 Quality Measure Guide" for more details.

- **Diabetes: HbA1c Control:** PH also accepts the Glucose Management Indicator (GMI) value, for patients using continuous glucose monitoring, for this measure.
- Diabetes: Kidney Health Evaluation: This measure has been added to the BCBSM/BCN incentive programs (It was a display-only measure in 2023)
- **Childhood Immunizations Flu:** In addition to the Combo 10 immunization series, BCBSM/BCN are incenting the Flu component as a separate measure.
- Frailty and Advanced Illness Criteria Guide: The guide was updated to account for billing code additions and deletions.
- Medication Adherence for Cholesterol, Diabetes, or Hypertension Medications: These measures have been added to the BCBSM/BCN incentive programs (Medicare product lines only).
- Social Determinants of Health (SDOH): Please note the following changes:
 - ➤ Beginning with the 2024 performance year, the BCBSM/BCN SDoH initiative no longer supports reporting Z-codes via claim. Therefore, this incentive is no longer available to NPO providers for BCBSM/BCN patients.
 - ➤ PH has added an SDoH screening component to its SDoH incentive. In addition to using Z-codes to report identified SDoH needs, NPO providers can submit the G-codes, below, to report SDoH screenings. Screening tool MUST address access to food, housing and transportation. SDoH screening and Z-Code Reporting are treated, and measured, as separate incentive measures. Please see NPO's "2024 Quality Measures Guide" for more information.
 - G9920: Screening performed and negative
 - G9919: Screening Performed and Positive and Provision of Recommendations

Additional Notes

- BCBSM/BCN is still allowing the manual entry of 2024 quality measure data into Health-e Blue.
- Currently, Priority Health is <u>NOT</u> allowing 2024 quality measure data to be entered manually; data submission via Patient Profile or Supplemental Report #70 has been disabled.
- Priority Health has added the Child and Adolescent Well Visits (ages 3-11) and Well-Child Visits in the First 30 Months of Life (0-15 months component) as Pediatric Focus Measures for 2024. The Chronic Disease Focus Measures, for adult practices, remain as Controlling High Blood Pressure and Diabetes: HbA1c (or GMI) ≤ 9%.